This article analyzes the financial performance of the Alzheimer's drug Leqembi within the Medicare program, revealing that actual spending is significantly lower than the $3.5 billion predicted by government actuaries for 2025. The piece explores the reasons behind this discrepancy, likely citing lower-than-expected utilization rates among seniors due to barriers such as the drug's high cost, complex administration requirements, and safety concerns. It highlights the broader economic implications for Medicare and the pharmaceutical industry.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.